Prevalence and incidence of young onset dementia and associations with comorbidities: A study of data from the French national health data system.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
01
02
2021
accepted:
08
09
2021
revised:
07
10
2021
pubmed:
24
9
2021
medline:
1
12
2021
entrez:
23
9
2021
Statut:
epublish
Résumé
Dementia onset in those aged <65 years (young onset dementia, YOD) has dramatic individual and societal consequences. In the context of population aging, data on YOD are of major importance to anticipate needs for planning and allocation of health and social resources. Few studies have provided precise frequency estimates of YOD. The aim of this study is to provide YOD prevalence and incidence estimates in France and to study the contribution of comorbidities to YOD incidence. Using data from the French national health data system (Système National des Données de Santé, SNDS) for 76% of the French population aged 40 to 64 years in 2016 (n = 16,665,795), we identified all persons with dementia based on at least 1 of 3 criteria: anti-Alzheimer drugs claims, hospitalization with the International Classification of Diseases-10th Revision (ICD-10) dementia codes (F00 to F03, G30, G31.0, G31.1, or F05.1), or registration for free healthcare for dementia. We estimated prevalence rate (PR) and incidence rate (IR) and estimated the association of comorbidities with incident YOD. Sex differences were investigated. We identified 18,466 (PRstandardized = 109.7/100,000) and 4,074 incident (IRstandardized = 24.4/100,000 person-years) persons with prevalent and incident YOD, respectively. PR and IR sharply increased with age. Age-adjusted PR and IR were 33% (95% confidence interval (CI) = 29 to 37) and 39% (95% CI = 31 to 48) higher in men than women (p < 0.001 both for PR and IR). Cardio- and cerebrovascular, neurological, psychiatric diseases, and traumatic brain injury prevalence were associated with incident YOD (age- and sex-adjusted p-values <0.001 for all comorbidities examined, except p = 0.109 for antihypertensive drug therapy). Adjustment for all comorbidities explained more than 55% of the sex difference in YOD incidence. The lack of information regarding dementia subtypes is the main limitation of this study. We estimated that there were approximately 24,000 and approximately 5,300 persons with prevalent and incident YOD, respectively, in France in 2016. The higher YOD frequency in men may be partly explained by higher prevalence of cardiovascular and neurovascular diseases, substance abuse disorders, and traumatic brain injury and warrants further investigation.
Sections du résumé
BACKGROUND
Dementia onset in those aged <65 years (young onset dementia, YOD) has dramatic individual and societal consequences. In the context of population aging, data on YOD are of major importance to anticipate needs for planning and allocation of health and social resources. Few studies have provided precise frequency estimates of YOD. The aim of this study is to provide YOD prevalence and incidence estimates in France and to study the contribution of comorbidities to YOD incidence.
METHODS AND FINDINGS
Using data from the French national health data system (Système National des Données de Santé, SNDS) for 76% of the French population aged 40 to 64 years in 2016 (n = 16,665,795), we identified all persons with dementia based on at least 1 of 3 criteria: anti-Alzheimer drugs claims, hospitalization with the International Classification of Diseases-10th Revision (ICD-10) dementia codes (F00 to F03, G30, G31.0, G31.1, or F05.1), or registration for free healthcare for dementia. We estimated prevalence rate (PR) and incidence rate (IR) and estimated the association of comorbidities with incident YOD. Sex differences were investigated. We identified 18,466 (PRstandardized = 109.7/100,000) and 4,074 incident (IRstandardized = 24.4/100,000 person-years) persons with prevalent and incident YOD, respectively. PR and IR sharply increased with age. Age-adjusted PR and IR were 33% (95% confidence interval (CI) = 29 to 37) and 39% (95% CI = 31 to 48) higher in men than women (p < 0.001 both for PR and IR). Cardio- and cerebrovascular, neurological, psychiatric diseases, and traumatic brain injury prevalence were associated with incident YOD (age- and sex-adjusted p-values <0.001 for all comorbidities examined, except p = 0.109 for antihypertensive drug therapy). Adjustment for all comorbidities explained more than 55% of the sex difference in YOD incidence. The lack of information regarding dementia subtypes is the main limitation of this study.
CONCLUSIONS
We estimated that there were approximately 24,000 and approximately 5,300 persons with prevalent and incident YOD, respectively, in France in 2016. The higher YOD frequency in men may be partly explained by higher prevalence of cardiovascular and neurovascular diseases, substance abuse disorders, and traumatic brain injury and warrants further investigation.
Identifiants
pubmed: 34555025
doi: 10.1371/journal.pmed.1003801
pii: PMEDICINE-D-21-00532
pmc: PMC8496799
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003801Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Neurol. 2002 Oct;59(10):1589-93
pubmed: 12374497
Trends Psychiatry Psychother. 2016 Jan-Mar;38(1):6-13
pubmed: 27074338
J Alzheimers Dis. 2020;75(3):697-704
pubmed: 32310170
J Alzheimers Dis. 2019;69(2):479-487
pubmed: 31006688
Dement Geriatr Cogn Disord. 2008;26(5):407-15
pubmed: 18946218
Lancet Neurol. 2010 Aug;9(8):793-806
pubmed: 20650401
Nervenarzt. 2006 Sep;77(9):1079-85
pubmed: 15959749
J Alzheimers Dis. 2019;69(4):1153-1160
pubmed: 31127765
Psychogeriatrics. 2020 Nov;20(6):817-823
pubmed: 32815229
Int Psychogeriatr. 2009 Aug;21(4):631-6
pubmed: 19470199
JAMA Psychiatry. 2015 Nov;72(11):1095-101
pubmed: 26444987
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Dement Geriatr Cogn Disord. 2014;38(5-6):271-80
pubmed: 24994018
Intern Med J. 2016 Jul;46(7):779-86
pubmed: 27405890
Brain Pathol. 2010 May;20(3):633-9
pubmed: 20522088
Psychosomatics. 2017 Jul - Aug;58(4):331-342
pubmed: 28501289
Am J Epidemiol. 2019 Jul 1;188(7):1213-1223
pubmed: 30824901
Rev Neurol (Paris). 2003 Apr;159(4):405-11
pubmed: 12773869
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S183-S197
pubmed: 28341166
Neurology. 1989 Jun;39(6):773-6
pubmed: 2725870
BMJ. 1993 Mar 13;306(6879):680-3
pubmed: 8471918
Alzheimers Dement. 2018 Aug;14(8):1038-1051
pubmed: 29621480
Neurology. 2010 Oct 5;75(14):1249-55
pubmed: 20810999
Am J Hum Genet. 1999 Sep;65(3):664-70
pubmed: 10441572
Alzheimers Dement. 2013 Jan;9(1):63-75.e2
pubmed: 23305823
Neurology. 2008 Nov 4;71(19):1496-9
pubmed: 18981371
PLoS One. 2017 Sep 8;12(9):e0184244
pubmed: 28886155
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1206-9
pubmed: 12933919
JAMA. 2012 Nov 7;308(17):1795-801
pubmed: 23117780
Psychiatr Clin North Am. 2015 Jun;38(2):249-64
pubmed: 25998114
Clin Epidemiol. 2019 Jul 05;11:509-518
pubmed: 31456649
Eur J Neurol. 2020 Jan;27(1):129-135
pubmed: 31330091
Mol Cell Neurosci. 2015 May;66(Pt B):75-80
pubmed: 25748121
Geriatr Psychol Neuropsychiatr Vieil. 2016 Jun 1;14(2):194-200
pubmed: 27277152
Int J Epidemiol. 1991 Sep;20(3):736-48
pubmed: 1955260
J Am Med Dir Assoc. 2013 Apr;14(4):230-2
pubmed: 23541136
Am J Epidemiol. 2019 Jul 1;188(7):1224-1227
pubmed: 30824902
Eur J Neurol. 2014 Apr;21(4):563-9
pubmed: 24418291
J Alzheimers Dis. 2018;61(4):1301-1310
pubmed: 29376854
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
BMC Geriatr. 2015 Jul 03;15:73
pubmed: 26135912
Alzheimers Dement. 2021 Jan;17(1):81-88
pubmed: 32914938
Int Psychogeriatr. 2014 Dec;26(12):1955-65
pubmed: 25307142
Neuroepidemiology. 2013;40(3):154-9
pubmed: 23257914
Psychiatry Clin Neurosci. 2014 Mar;68(3):216-24
pubmed: 24372910
Neuroepidemiology. 1999;18(3):144-55
pubmed: 10202268
J Alzheimers Dis. 2017;60(3):1045-1054
pubmed: 28984595
Alzheimers Dement. 2018 Feb;14(2):130-139
pubmed: 28734783
J Am Geriatr Soc. 2004 Feb;52(2):195-204
pubmed: 14728627
Psychol Med. 2013 Feb;43(2):423-32
pubmed: 22640548
J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):959-64
pubmed: 25406350
Neurology. 2002 Jun 11;58(11):1615-21
pubmed: 12058088
Geriatr Gerontol Int. 2020 Nov;20(11):1050-1055
pubmed: 32989857
Alzheimers Dement (N Y). 2019 Nov 19;5:789-796
pubmed: 31921967
Mol Cell Endocrinol. 2014 May 25;389(1-2):7-12
pubmed: 24508665
Emerg Themes Epidemiol. 2011 May 15;8(1):4
pubmed: 21569640